Seminars in Thoracic and Cardiovascular Surgery最新文献

To validate the efficiency of pathologic grading system in pathologic stage IA lung adenocarcinoma (LUAD), and explore whether integrating preoperative radiological features would enhance the performance of recurrence discrimination. We retrospectively collected 510 patients with resected stage IA LUAD between January 2012 and December 2019 from Guangdong Provincial People's Hospital (GDPH). Pathologic grade classification of each case was based on the International Association for the Study of Lung Cancer (IASLC) pathologic staging system. Kaplan-Meier curves was used to assess the power of recurrence stratification. Concordance index (C-Index) and receiver operating characteristic curves (ROC) were used for evaluating the clinical utility of different grading systems for recurrence discrimination. Patients of lower IASLC grade showed improved recurrence-free survival (RFS) (P < 0.0001) where numerically difference was found between grade II and grade III (P = 0.119). By integrating the IASLC grading system and radiological feature, we found the RFS rate decreased as the novel radiopathological (RP) grading system increased (P < 0.0001). The difference of RFS curves between any 2 groups as per the RP grading system was statisticallysignificant (RP grade I vs RP grade II, p = 0.007; RP grade I vs RP grade III, P < 0.0001; RP grade II vs RP grade III, P = 0.0003). Compared with the IASLC grading system, the RP grading system remarkably improved recurrence survival discrimination (C-index: 0.822; area under the curve, 0.845). Integrating imaging features into pathologic grading system enhanced the efficiency of recurrence discrimination for resected stage IA LUAD and might help conduct subsequent management.

Many cardiothoracic surgeons have become less involved in the process of developing therapies and diagnostic tools. There is renewed interest in innovation as a discipline among early career cardiothoracic surgeons and trainees. We describe the role and the essential skillsets that cardiothoracic surgeons must be adopt in order to successfully contribute to medical product innovation

There is continued controversy regarding surgical management of patients with hypertrophic cardiomyopathy (HCM) and intrinsic mitral valve disease; some clinicians favor prosthetic replacement as this corrects left ventricular outflow tract (LVOT) obstruction and valve leakage. In this study, we investigated the management and late outcome of operation for mitral regurgitation (MR) due to ruptured chordae tendineae in patients with HCM. We analyzed 49 consecutive patients with HCM and MR due to ruptured mitral valve chordae. Echocardiograms and operative reports were reviewed to classify valve anatomy and surgical methods. Information on late outcomes was obtained from electronic medical records and follow-up surveys. The mean age of the 36 men and 13 women was 61.9 ± 12.5 years; significant resting or provoked LVOT obstruction was present at the time of surgery in 46 patients. During the index operation, mitral valve repair was performed in 45 patients, and prosthetic replacement was necessary for 4 patients. Concomitant septal myectomy was performed in 46 patients. There were no hospital deaths or deaths within 30 days of operation. Five and ten-year survival estimates (Kaplan-Meier) were 92% and 71%. During follow-up at a median of 7.9 years, 3 patients underwent reoperation for MV replacement, 5 days, 3 years, and 14 years following valve repair. Ruptured mitral chordae may result in severe mitral valve regurgitation in patients with hypertrophic cardiomyopathy. Valvuloplasty at the time of septal myectomy is safe with an acceptably low rate of recurrent MR requiring prosthetic replacement.

Thoracoscopic surgery for congenital lung malformations (CLMs) has been widely used. However, there are still many shortcomings in the current surgical methods, such as the removal of some normal lung tissue and residual lesions. Thoracoscopic anatomical lesion resection (TALR) may be an effective and safe method to resolve these problems. This retrospective study was conducted to estimate the safety and efficiency of TALR. A retrospective review of clinical data involving patients who underwent TALR in our hospital from October 2019 to January 2021 was performed. Clinical data, including patients’ demographic characteristics, manipulative details, and postoperative complications, were extracted and analyzed. A total of 95 cases were included in this study. All cases were operated on under thoracoscope, with no conversion to open surgery. The average operation time was 63.2 ± 15.2 min (range 36−142 min). The average bleeding volume during the operation was 5.8 ± 2.1 mL (range 2−10 mL). The mean diameter of the lesion was 4.4 ± 1.9 cm (range 3−7 cm). All cases had no complications, such as bronchopleurothelial fistula, hemorrhage, atelectasis, or pulmonary infection. Two patients developed pneumothorax 1 month after the operation and were cured by closed thoracic drainage. One month after the operation, chest CT showed regular cysts in 2 cases. The other patients were followed up for over 1 year by chest CT after the operation, and all recovered well without residual lesions or recurrence. Combined with the preoperative thin slice CT and intraoperative lesion boundary, anatomical intrapulmonary dissociation based on the pulmonary vein system, TALR, as a lung-sparing surgery of completely removing the lesion and retaining all normal lung tissue, has high safety and effectiveness in the treatment of CLMs.

We assessed the incidence of competitive flow with early postoperative angiograms in patients who received a “no-touch” saphenous vein (NT SV) composite graft and reexamined the status of competitive flow at 1-year. Early postoperative angiograms were performed in 806 patients who underwent myocardial revascularization using a NT SV Y-composite graft based on the in situ left internal thoracic artery (LITA). Competitive conduit flow was observed in 102 distal anastomoses (102 of 3039 [3.4%] anastomoses) of 94 patients (94 of 806 [11.7%]; NT SV competitive flow in 74 and LITA competitive flow in 20). Of the 94 patients, 63 patients (50 with NT SV competition and 13 with LITA competition) were re-evaluated with 1-year postoperative angiograms. Fifty-six competitive NT SV conduits in 50 patients were reevaluated at 1-year postoperatively: 44 (78.6%) early competitive anastomoses had become patent and 12 (21.4%) were occluded. NT SV with pedicle tissue showed a higher tendency of being perfectly patent at 1-year postoperatively than NT SV without pedicle tissue (17 of 40 [42.5%] vs 2 of 16 [12.5%]; P = 0.007). Thirteen competitive LITA conduit anastomoses in 13 patients were reevaluated 1-year postoperatively: 9 (69.2%) early competitive anastomoses had become patent and 4 (30.8%) were occluded. Competitive flow was shown on early postoperative angiograms in 3.4% of distal anastomoses in patients who received NT SV Y-composite grafts. Approximately 80% of the competitive NT SV conduits were patent 1-year postoperatively, and perfect patency rates were higher in patients who had received NT SV with pedicle tissue than in patients who had received NT SV without pedicle tissue.